BioMarin said it signed an agreement with Hanmi and GC Biopharma for HM15421/GC1134A (LA-GLA), a next-generation enzyme replacement therapy designed to extend exposure using Hanmi’s long-acting drug technology. The candidate pairs a recombinant alpha-galactosidase A formulation with a delivery approach aimed at enabling subcutaneous administration rather than biweekly intravenous dosing typical of conventional ERTs. BioMarin received worldwide rights, while Korea commercialization and regulatory approval responsibilities remain with GC and Hanmi. The deal includes development and commercial milestone payments that could reach $405 million, highlighting continued investor interest in differentiated lysosomal storage disease platforms as Fabry competitive dynamics intensify.